{"Title": "Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial", "Year": 2019, "Source": "PLoS ONE", "Volume": "14", "Issue": 1, "Art.No": null, "PageStart": null, "PageEnd": null, "CitedBy": 8, "DOI": "10.1371/journal.pone.0209911", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060631958&origin=inward", "Abstract": "\u00a9 2019 Bernardino et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Background Comparison of changes in body composition, adipokines and inflammatory markers after initial therapy with a nucleos(t)ide reverse transcriptase inhibitor (N(t)RTI)- sparing or containing regimen are scarce. Design Randomised Clinical Trial. Methods This is the body composition substudy of NEAT 001/ANRS 143, a randomised trial comparing darunavir/ritonavir (DRV/r) plus either raltegravir (RAL) or tenofovir disoproxil fumarate/ emtricitabine (TDF/FTC) in 805 ART na\u00efve HIV-infected adults. The primary endpoint was percentage change in limb fat at week 96. Secondary endpoints were associations among these changes and metabolic markers (IL-6, insulin, leptin, adiponectin, FGF-23). Results 126 subjects (61 DRV/r + RAL and 65 DRV/r + TDF/FTC) were included. The rate of change in BMI between groups for RAL versus TDF/FTC at week 96 was 1.5% per 48-week period (p = 0.015). The rate of change in limb fat mass, trunk fat mass, total body fat and total lean mass was for RAL versus TDF/FTC at week 96 was 2.5% (p = 0.38), 7.3% ((p = 0.021), 4.9% (p = 0.061) and 1.3% (p = 0.12) respectively. Baseline insulin and leptin levels were correlated with baseline limb fat and trunk fat mass [r = 0.31 (p = 0.0043)/r = 0.28 (p = 0.0011) for limb fat, and r = 0.63 (p<0.0001)/r = 0.50(p<0.0001) for trunk fat]. After adjustment, a 10% faster increase in leptin between baseline and week 48 was associated with a more rapid increase in limb fat at week 48 (0.5% per 48 weeks, p<0.001), total body fat mass (0.6% per 48 weeks, p<0.001), and trunk fat mass (0.3% per 48 weeks, p = 0.0026). Conclusions After week 96 a N(t)RTI sparing regimen of DRV/r + RAL produced a numerically greater percentage increase in body composition variables with only change in trunk fat mass and BMI being significant.", "AuthorKeywords": null, "IndexKeywords": ["Adipokines", "Adult", "Body Composition", "Body Mass Index", "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination", "Female", "Humans", "Male", "Raltegravir Potassium", "Time Factors"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85060631958", "SubjectAreas": [["Biochemistry, Genetics and Molecular Biology (all)", "BIOC", "1300"], ["Agricultural and Biological Sciences (all)", "AGRI", "1100"], ["Multidisciplinary", "MULT", "1000"]], "AuthorData": {"12752835500": {"Name": "Bernardino J.I.", "AuthorID": "12752835500", "AffiliationID": "60028162, 60106529", "AffiliationName": "Department of Internal Medicine, Hospital Universitario La Paz, IdiPAZ"}, "24821482800": {"Name": "Arribas J.R.", "AuthorID": "24821482800", "AffiliationID": "60028162, 60106529", "AffiliationName": "Department of Internal Medicine, Hospital Universitario La Paz, IdiPAZ"}, "7006513758": {"Name": "Mocroft A.", "AuthorID": "7006513758", "AffiliationID": "60022148", "AffiliationName": "University College London"}, "6506583322": {"Name": "Wallet C.", "AuthorID": "6506583322", "AffiliationID": "60102125, 60008134, 60000905, 60116091", "AffiliationName": "University of Bordeaux INSERM, Bordeaux Population Health Research Center, UMR 1219"}, "22958707400": {"Name": "Richert L.", "AuthorID": "22958707400", "AffiliationID": "60102125, 60008134, 60000905, 60116091", "AffiliationName": "University of Bordeaux INSERM, Bordeaux Population Health Research Center, UMR 1219"}, "57203665572": {"Name": "De Wit S.", "AuthorID": "57203665572", "AffiliationID": "60029852, 60000145", "AffiliationName": "CHU Saint Pierre, Universit\u00e9 Libre de Bruxeles"}, "57203678301": {"Name": "Katlama C.", "AuthorID": "57203678301", "AffiliationID": "60001422, 60015622, 60139056", "AffiliationName": "H\u00f4pital Piti\u00e9 Salp\u00e9tri\u00e8re, Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique"}, "7005073010": {"Name": "Reiss P.", "AuthorID": "7005073010", "AffiliationID": "60002483, 60001157", "AffiliationName": "Department of Global Health, Division of Infectious Diseases, Academic Medical Center, University of Amsterdam"}, "24471642700": {"Name": "Mallon P.W.", "AuthorID": "24471642700", "AffiliationID": "60005141", "AffiliationName": "School of Medicine, University College Dublin"}, "7201417014": {"Name": "Molina J.M.", "AuthorID": "7201417014", "AffiliationID": "60002900, 60123796, 60000905", "AffiliationName": "H\u00f4pital Saint-Louis, University of Paris Diderot, INSERM U941"}, "7005643531": {"Name": "Knobel H.", "AuthorID": "7005643531", "AffiliationID": "60023020, 60023506", "AffiliationName": "Department of Infectious Diseases, Hospital del Mar, Universidad Aut\u00f3noma de Barcelona"}, "7005125316": {"Name": "Morlat P.", "AuthorID": "7005125316", "AffiliationID": "60102125, 60116091, 60021564", "AffiliationName": "Service de Medicine Interne et Maladies Infectieuses, CHU Bordeaux, Universit\u00e9 de Bordeaux, Inserm U 1219"}, "7004544555": {"Name": "Babiker A.", "AuthorID": "7004544555", "AffiliationID": "60003108, 60022148", "AffiliationName": "MRC Clinical Trials Unit at UCL"}, "57205572822": {"Name": "Pozniac A.", "AuthorID": "57205572822", "AffiliationID": "60032993", "AffiliationName": "Chelsea and Westminster hospital NHS Foundation Trust"}, "57210126396": {"Name": "Raffi F.", "AuthorID": "57210126396", "AffiliationID": "60028048, 60000905", "AffiliationName": "Department of infectious diseases, CHU de Nantes, CIC 1413, INSERM"}, "null": {"Name": null, "AuthorID": null, "AffiliationID": null, "AffiliationName": null}}}